A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer

NCT03093272 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

9

Enrollment

OTHER

Sponsor class

Stopped Safety concerns

Conditions

Prostate Cancer

Interventions

DRUG: Leuprolide Acetate
DRUG: Prednisone
DRUG: Docetaxel
DRUG: Apalutamide

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]